Korea-based biopharmaceutical company Medytox has reportedly revamped its strategy for entering the Chinese market, according to Koreabiomed.com. After withdrawing a drug registration filing for its Meditoxin/Neuronox (Botulinum toxin type A; BTX) with the National Medical Products Administration (NMPA) in 2018, Medytox is now setting its sights on introducing Newlux, a next-generation BTX product developed by its subsidiary Numeco.
Newlux: Enhanced Safety and Efficiency
Newlux, a freeze-dried powder formulation of Botulinum toxin type A, offers enhanced safety by eliminating animal-derived ingredients from its production process. This innovation not only improves the safety profile of the product but also boosts production yield and purity. The drug received approval in South Korea in September of this year, marking a significant step forward in Medytox’s product development.
Market Entry and Manufacturing Capacity
Medytox is well-prepared for the Chinese market, with sufficient existing manufacturing capacity to support the launch of Newlux. The company is also actively seeking domestic partners in China to facilitate the market entry and distribution of its new product, highlighting its commitment to expanding its global footprint and leveraging local expertise.-Fineline Info & Tech
